Table of Contents  
RESEARCH LETTER
Year : 2011  |  Volume : 2  |  Issue : 2  |  Page : 114-115  

HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients


1 National Institute of Immunohaematology, 13th Floor, KEM Hospital, Parel, Mumbai - 400 012, India
2 Department of Medicine, ART Centre, KEM Hospital, Parel, Mumbai - 400 012, India

Date of Web Publication6-Jun-2011

Correspondence Address:
Shankarkumar Umapathy
National Institute of Immunohaemtology, 13th Floor, KEM Hospital, Parel, Mumbai - 400 012, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0976-500X.81905

Rights and Permissions

How to cite this article:
Umapathy S, Pawar A, Bajpai S, Pazare A R, Ghosh K. HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients. J Pharmacol Pharmacother 2011;2:114-5

How to cite this URL:
Umapathy S, Pawar A, Bajpai S, Pazare A R, Ghosh K. HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients. J Pharmacol Pharmacother [serial online] 2011 [cited 2019 Aug 22];2:114-5. Available from: http://www.jpharmacol.com/text.asp?2011/2/2/114/81905

Sir,

Nevirapine is a non-nucleoside reverse transcriptase inhibitor used commonly in antiretroviral (ARV) treatment in India. Several studies have suggested and documented that HLA antigen plays a major role in this phenomenon. However, to our knowledge limited literature is available from India. Therefore, we investigated the role of HLA on nevirapine-induced rash among the antiretroviral treated HIV-1-positive infected individuals from India.

As per National AIDS Control Organization (NACO) under Ministry of Health and Family Welfare, the first regimen is given to patients in a combination of three drugs as follows: Stavudine+Lamivudine+Nevirapine (SLN); Stavudine +Lamivudine+Efavirenz (SLE); Zidovudine+Lamivudine+Nevirapine (ZLN); and Zidovudine +Lamivudine+Efavirenz (ZLE). Currently, there are 26 antiretroviral (ARV) agents' divided into four classes: Reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, and integrase inhibitors. [1]

Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with high antiretroviral efficacy. [1] NVP-based HAART regimens are widely used in resource-limited countries like India. Nevirapine is associated with hypersensitivity reactions (HSR) like fever, hepatitis, skin rash [1] with clinical complications. By a recent meta-analysis, approximately 50% of these were associated with rash. Several features of nevirapine hypersensitivity suggest that genetic factors may play an important role, and that nevirapine-specific antigens may trigger immunological response that is dependent on the CD4+T lymphocyte and CD8+T lymphocyte-related response of the patient. [2] Most nevirapine-associated hypersensitivity occurs within 14 to 21 days of drug administered and is more rapid and severe if re-challenged. [2] Therefore, we investigated the role of HLA on nevirapine-induced rash among the antiretroviral-treated HIV-1-infected individuals from India.

This case controlled study included a total of 40 HIV-1-infected patients who developed nevirapine-induced specific skin rash after treatment, and 40 HIV-1-infected patients who tolerated the drug were selected and compared The institutional Ethics committee's approval was obtained for the study. A clinical Performa, filled up for the patients with consent. For HLA from each patient 5 ml of peripheral blood in BD Sodium Heparin Vacutainer was collected by vein puncture. The HLA typing was done using specific HLA antisera by a two-stage microlymphocytotoxicity assay. The statistical analysis for the antigen gene frequency was carried out using the Chi-square test with Yates correction. The 95% confidence intervals were calculated for etiological fraction and preventive fraction. P values<0.05 were considered significant.

Clinically, among the nevirapine-induced rash cases we observed that all are positive for HIV-1. Most of the patients were females (52.5%) than males (47.5%), among nevirapine-induced skin rash-positive patients, 10% presented with Steven-Johnson syndrome, 7.5% had hepatitis, all patients had skin rash, while some had fever and pruritus. The distribution of HLA antigens among the nevirapine-induced hypersensitivity reactive HIV-1-positive patients is presented [Table 1]. Our results revealed a highly significant association of HLA B35 (OR: 3.378; P value 0.0032) with nevirapine-induced skin rash. Further, a significant HLA B7 (OR: 0.292; P value 0.0085); HLA B8 (OR: 0.272; P value 0.0825) and HLA B15 (OR: 0.272; P value 0.0825) were also found to be decreased significantly among the nevirapine-hypersensitive patients.
Table 1: Distribution of HLA antigens among the nevirapine-induced hypersensitivity in HIV-1-positive patients

Click here to view


NVP-associated rash has been reported to be as high as 48% after the treatment with this inhibitor [6] . The rash associated with nevirapine is a distinct clinical and pathophysiological entity. Skin rash is the most common adverse drug reaction associated with NVP, and hypersensitivity reaction to NVP is rapid and severe when drug administration is suspended and re-challenged. NVP induced rash has been reported in 4.3-36% of adults [3] with prevalence for Thai HIV patients ranging from 6% to -21%. [4] In Sardinian population were HLA B14 and Cw8 was associated 26% developed NVP induced rash, in our study from India we found that NVP-induced rash was 2.14%, thus, reflecting the comparatively a high incidence of drug-related rash in Asians. [5] Recent studies have shown that hypersensitivity reactions to antiretroviral drugs are HLA-associated. HIV-infected Thai patients have a significant HLA Cw*04 allele association with nevirapine induced rash cases. [4] HLA B*3505 allele has been identified as a strong predictor for nevirapine-induced skin adverse reactions in Thai HIV patients. [6] This study shows that HLA B35 is significantly associated among the nevirapine-induced skin rash HIV-1 ARV-treated patients of India. Further, the molecular HLA characterization of these alleles will enlighten us on the immunological basis of the antiretroviral drug reactions.

 
   References Top

1.Harminder S, Dulhani N, Tiwari P, Singh P, Sinha T. A prospective observational cohort study to elicit adverse effects of antiretroviral agents in a remote resourse-restricted tribal population of Chhattisgarh. Indian J Pharmacol 2009;41:224-8.  Back to cited text no. 1
    
2.Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury with the use of nonnucleoside reverse transcriptase inhibitors Clin Infect Dis 2004;38:S80-9.  Back to cited text no. 3
    
4.Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Tunthanathip P, et al. HLA Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai Patients. AIDS Res Ther 2009;6:22.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Littera R, Carcassi C, Masala A, Plano P, Serra P, Ortu F, et al. HLA dependant hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006;20:1621-6.  Back to cited text no. 5
    
6.Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, et al. HLA B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV infected Thai patients. Pharmacogenet Genomics 2009;19:139-46.  Back to cited text no. 6
[PUBMED]  [FULLTEXT]  



 
 
    Tables

  [Table 1]


This article has been cited by
1 Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex
Makoto Hirasawa,Katsunobu Hagihara,Koji Abe,Osamu Ando,Noriaki Hirayama
International Journal of Molecular Sciences. 2018; 19(6): 1660
[Pubmed] | [DOI]
2 Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles
Rebecca Pavlos,Elizabeth J. McKinnon,David A. Ostrov,Bjoern Peters,Soren Buus,David Koelle,Abha Chopra,Ryan Schutte,Craig Rive,Alec Redwood,Susana Restrepo,Austin Bracey,Thomas Kaever,Paisley Myers,Ellen Speers,Stacy A. Malaker,Jeffrey Shabanowitz,Yuan Jing,Silvana Gaudieri,Donald F. Hunt,Mary Carrington,David W. Haas,Simon Mallal,Elizabeth J. Phillips
Scientific Reports. 2017; 7(1)
[Pubmed] | [DOI]
3 HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity
Elena M. Cornejo Castro,Daniel F. Carr,Andrea L. Jorgensen,Ana Alfirevic,Munir Pirmohamed
Pharmacogenetics and Genomics. 2015; 25(4): 186
[Pubmed] | [DOI]
4 Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
V. L. M. Yip,A. Alfirevic,M. Pirmohamed
Clinical Reviews in Allergy & Immunology. 2014;
[Pubmed] | [DOI]
5 Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapineæs Epitaph?
Fred Stephen Sarfo,Maame Anima Sarfo,Betty Norman,Richard Phillips,David Chadwick,Julius Atashili
PLoS ONE. 2014; 9(4): e94854
[Pubmed] | [DOI]
6 DRESS Syndrome due to Nevirapine Treated with Methylprednisolone
Henrique Pott Junior,Gisele Cristina Gosuen,Ana Cristina Gales
Case Reports in Medicine. 2013; 2013: 1
[Pubmed] | [DOI]
7 Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population
Carr, D.F. and Chaponda, M. and Jorgensen, A.L. and Castro, E.C. and Van Oosterhout, J.J. and Khoo, S.H. and Lalloo, D.G. and Heyderman, R.S. and Alfirevic, A. and Pirmohamed, M.
Clinical Infectious Diseases. 2013; 56(9): 1330-1339
[Pubmed]
8 Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population
D. F. Carr,M. Chaponda,A. L. Jorgensen,E. C. Castro,J. J. van Oosterhout,S. H. Khoo,D. G. Lalloo,R. S. Heyderman,A. Alfirevic,M. Pirmohamed
Clinical Infectious Diseases. 2013; 56(9): 1330
[Pubmed] | [DOI]



 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Tables

 Article Access Statistics
    Viewed1328    
    Printed88    
    Emailed0    
    PDF Downloaded310    
    Comments [Add]    
    Cited by others 8    

Recommend this journal